Cardiol TherapeuticsCRDL
About: Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Employees: 18
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
3,660% more call options, than puts
Call options by funds: $188K | Put options by funds: $5K
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
3% more funds holding
Funds holding: 40 [Q3] → 41 (+1) [Q4]
2.05% more ownership
Funds ownership: 7.12% [Q3] → 9.17% (+2.05%) [Q4]
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
3% less capital invested
Capital invested by funds: $9.85M [Q3] → $9.59M (-$265K) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Vernon Bernardino 15% 1-year accuracy 11 / 71 met price target | 805%upside $9 | Buy Reiterated | 16 Apr 2025 |
Financial journalist opinion
Based on 3 articles about CRDL published over the past 30 days









